Fig. 3From: Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose studyPharmacokinetics of MEDI-551. Serum concentration-time profile of MEDI-551 following a single IV administrationBack to article page